Personalized care in neuro-oncology coming of age: Why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

Neuro-Oncology

Volumn 14, Issue SUPPL.4, 2012, Pages

  Weller, Michael ^a   Stupp, Roger ^b   Hegi, Monika E ^b   Van Den Bent, Martin ^c   Tonn, Joerg C ^d   Sanson, Marc ^e   Wick, Wolfgang ^f,g   Reifenberger, Guido ^h  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MUNICH   (Germany)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

1p 19q; gliomas; IDH 1; MGMT; prognosis

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL PRACTICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOMA; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEUROLOGY; PATHOLOGY, MOLECULAR; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84868019401     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos206     Document Type: Article

References (51)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
2. Hegi ME, Janzer RC, Lambiv WL, et al. Presence of an oligodendroglioma- like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial. Acta Neuropathol. 2012;123:841-852.
3. Van den Bent M. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010;120:297-304.
4. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175-1190. (Pubitemid 24345665)
5. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861. (Pubitemid 44672036)
6. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333:1453-1455.
7. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226:7-16.
8. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligo-dendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. 2012;123:853-860.
9. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714. (Pubitemid 46630566)
10. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarba-zine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722. (Pubitemid 46630567)
11. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2009;27:5874-5880.
12. Cairncross JG, Wang M, Shaw EG, et al. Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendro-glioma: long-term results of the RTOG 9402 phase III study. [Abstract] J Clin Oncol. 2012;30:2008b.
13. Van den Bent MJ, Hoang-Xuan K, Brandes AA, et al. Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). [Abstract] J Clin Oncol. 2012;30:2.
14. Weller M, Felsberg J, Hartmann C, et al., for the German Glioma Network. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective transla-tional study of the German Glioma Network. J Clin Oncol. 2009;27:5743-5750.
15. Weller M, Berger H, Hartmann C, et al., for the German Glioma Network. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res. 2007;13:6933-6937. (Pubitemid 350276872)
16. Hartmann C, Hentschel B, Tatagiba M, et al., for the German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588-4599.
17. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61:484-490. (Pubitemid 46878776)
18. Gozé C, Bezzina C, Gozé E, et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012;108:69-75.
19. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857. (Pubitemid 29001538)
20. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkyl-ating agents. N Engl J Med. 2000;343:1350-1354.
21. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
22. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and response to temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
23. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol. 2010;6:39-51.
24. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial ster-eotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer. 2007;121:2458-2464. (Pubitemid 350022415)
25. Felsberg J, Thon N, Eigenbrod S, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011;129:659-670.
26. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). [Abstract] J Clin Oncol. 2011;29:2006.
27. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131:1342-1350.
28. Gá llego Pé rez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29:3050-3055.
29. Wick W, Platten M, Meisner C, et al. for the NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707-715.
30. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy for patients aged over 60 years with glioblastoma: the Nordic randomized phase 3 trial. Lancet Oncol. 2012. in press.
31. Stupp R, Hegi ME, Neyns B, et al. Phase I//IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712-2718.
32. Van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27:5881-5886.
33. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astroctytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavourable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707-718.
34. van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype in anaplastic oligodendroglial brain tumors is a better predictor of survival than MGMT methylation in anaplastic oligodendro-glioma: a report from EORTC study 26951. Clin Cancer Res. 2011;17:7148-7155.
35. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483:479-483.
36. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in malignant gliomas: depends on IDH1 mutations. [Abstract] Neuro-Oncology. 2012.
37. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012. In press.
38. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597-602.
39. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
40. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
41. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 2009;73:1792-1795.
42. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
43. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
44. Capper D, Simon M, Langhans CD, et al. 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer. 2012;131:766-768.
45. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas. Nature Med. 2012;18:624-629.
46. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology. 2011;13:307-316.
47. Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocy-tomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. 2012;118:452-460.
48. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173. (Pubitemid 43357943)
49. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
50. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
51. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.